A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions

Affiliations

• ¹ Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ² Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy.
• ³ Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome, Italy.
• ⁴ Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ⁵ Department of Molecular Medicine, University of Padua, Padua, Italy.
• ⁶ Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ⁷ SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ⁸ Scientific Direction, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
• ⁹ Department of Pathology, Biobank, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹⁰ Laboratory of Oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013, Italy.
• ¹¹ Thoracic Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹² Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹³ Scientific Direction Office, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹⁴ Breast Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ¹⁵ IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
• ¹⁶ Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. giovanni.blandino@ifo.it.